These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25639617)

  • 41. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
    Nicholaou T; Wong R; Davis ID
    Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
    [No Abstract]   [Full Text] [Related]  

  • 42. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.
    Fountzilas G; Fragkoulidi A; Kalogera-Fountzila A; Nikolaidou M; Bobos M; Calderaro J; Andreiuolo F; Marselos M
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):649-60. PubMed ID: 19655144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Skin ulcers in Klippel-Trenaunay syndrome respond to sunitinib.
    Nguyen S; Franklin M; Dudek AZ
    Transl Res; 2008 Apr; 151(4):194-6. PubMed ID: 18355766
    [No Abstract]   [Full Text] [Related]  

  • 44. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
    Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
    Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
    [No Abstract]   [Full Text] [Related]  

  • 45. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
    Shojaei F; Simmons BH; Lee JH; Lappin PB; Christensen JG
    Cancer Lett; 2012 Jul; 320(1):48-55. PubMed ID: 22269210
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients.
    Kanefendt F; Lindauer A; Kinzig M; Strumberg D; Scheulen ME; Mross K; Fischer R; Moritz B; Sörgel F; Jaehde U
    Int J Clin Pharmacol Ther; 2011 Jan; 49(1):88-90. PubMed ID: 21176741
    [No Abstract]   [Full Text] [Related]  

  • 47. Beyond the maths of biology: long-term spontaneous tumoral regression after sunitinib withdrawal.
    Teo M; Downey FP; McDermott RS
    Clin Genitourin Cancer; 2013 Jun; 11(2):198-200. PubMed ID: 23276590
    [No Abstract]   [Full Text] [Related]  

  • 48. Molecular basis for sunitinib efficacy and future clinical development.
    Faivre S; Demetri G; Sargent W; Raymond E
    Nat Rev Drug Discov; 2007 Sep; 6(9):734-45. PubMed ID: 17690708
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A differential response to sunitinib: sustained systemic response paralleled by intra-dural progression in the spine. Should standard response criteria be reviewed?
    Jafri M; Porfiri E
    Clin Genitourin Cancer; 2009 Aug; 7(2):E42-4. PubMed ID: 19692324
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors.
    Tobin NP; Wennmalm K; Lindström LS; Foukakis T; He L; Genové G; Östman A; Landberg G; Betsholtz C; Bergh J
    Clin Cancer Res; 2016 May; 22(10):2417-26. PubMed ID: 26769751
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.
    De Giorgi U; Scarpi E; Sacco C; Aieta M; Lo Re G; Sava T; Masini C; De Vincenzo F; Baldazzi V; Camerini A; Fornarini G; Burattini L; Rosti G; Ferrari V; Moscetti L; Chiuri VE; Luzi Fedeli S; Amadori D; Basso U
    Clin Genitourin Cancer; 2014 Jun; 12(3):182-9. PubMed ID: 24369790
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe perirenal hematoma in a patient with a single kidney treated with sunitinib for metastatic pancreatic neuroendocrine tumor.
    Zugazagoitia J; Sastre J; Barrera J; García B; Díaz-Rubio E
    J Cancer Res Ther; 2012; 8(2):303-5. PubMed ID: 22842382
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Angiosarcoma of the scalp successfully treated with pazopanib.
    Tomita H; Koike Y; Asai M; Ogawa F; Abe K; Tanioka M; Utani A
    J Am Acad Dermatol; 2014 Jan; 70(1):e19-21. PubMed ID: 24176520
    [No Abstract]   [Full Text] [Related]  

  • 55. Early development of sunitinib in hepatocellular carcinoma.
    Zhu AX; Raymond E
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):143-50. PubMed ID: 19105714
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors.
    Kuenen BC
    Pathophysiol Haemost Thromb; 2003; 33 Suppl 1():13-4. PubMed ID: 12954992
    [No Abstract]   [Full Text] [Related]  

  • 57. Mutational landscape of primary breast angiosarcoma with repeated resection and recurrence over a 15-year period: A case report.
    Teruyama F; Kuno A; Murata Y; Nakagawa T; Shiba-Ishii A; Yuguchi S; Noguchi M
    Pathol Int; 2022 Sep; 72(9):457-463. PubMed ID: 35801418
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survival in angiosarcoma of the breast.
    Smoron GL
    JAMA; 1978 Aug; 240(8):737-8. PubMed ID: 566804
    [No Abstract]   [Full Text] [Related]  

  • 59. Recurrent PTPRB and PLCG1 mutations in angiosarcoma.
    Behjati S; Tarpey PS; Sheldon H; Martincorena I; Van Loo P; Gundem G; Wedge DC; Ramakrishna M; Cooke SL; Pillay N; Vollan HKM; Papaemmanuil E; Koss H; Bunney TD; Hardy C; Joseph OR; Martin S; Mudie L; Butler A; Teague JW; Patil M; Steers G; Cao Y; Gumbs C; Ingram D; Lazar AJ; Little L; Mahadeshwar H; Protopopov A; Al Sannaa GA; Seth S; Song X; Tang J; Zhang J; Ravi V; Torres KE; Khatri B; Halai D; Roxanis I; Baumhoer D; Tirabosco R; Amary MF; Boshoff C; McDermott U; Katan M; Stratton MR; Futreal PA; Flanagan AM; Harris A; Campbell PJ
    Nat Genet; 2014 Apr; 46(4):376-379. PubMed ID: 24633157
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Status of microsatellite stability in angiosarcoma: Angiosarcoma is a microsatellite stable tumor.
    Maeda-Otsuka S; Myangat TM; Kajihara I; Sakamoto R; Yamada-Kanazawa S; Sawamura S; Makino K; Masuguchi S; Fukushima S; Ihn H
    J Dermatol; 2021 Aug; 48(8):e368-e369. PubMed ID: 33914950
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.